Veeva(US:VEEV) ZACKS·2024-07-24 17:05Company Insights - Boston Scientific has a Zacks Rank of 2 and an estimated long-term growth rate of 12.5% [1] - Boston Scientific's earnings have exceeded estimates in the last four quarters, with an average surprise of 7.5% [1] - Boston Scientific's shares have increased by 46.3% over the past year, contrasting with a 1.8% decline in the industry [2] Veeva Systems Developments - Veeva Systems has partnered with Vita Global Sciences to enhance clinical data management processes [3] - The adoption of Veeva Vault EDC is expected to improve Vita Global's study designs and data management efficiency [4][5] - Veeva Systems' management anticipates that the partnership will accelerate study builds and improve patient outcomes [5] Industry Prospects - The global clinical data management system market is projected to grow from $2.3 billion in 2022 to $5.42 billion by 2030, with a CAGR of 11.3% [6] - The growth is driven by an increasing number of clinical trials and integration with healthcare technologies [6] - The recent product adoption is expected to enhance Veeva Systems' global business [7] Notable Developments - Veeva Vault EDC was selected by Hangzhou Tigermed Consulting as its technology foundation for modern EDC [8] - Veeva Systems announced that three top 20 biopharmas selected multiple Veeva Development Cloud Applications in the first quarter of fiscal 2025 [8] - Veeva Vault Basics, a new offering for biotechs, was launched and is currently available in North America [9] Price Performance - Veeva Systems' shares have decreased by 5.8% over the past year, while the industry has risen by 22.3% and the S&P 500 by 22.6% [10]